Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials
Pharmacology, Toxicology and Pharmaceutical Science
10
5%
Agricultural and Biological Sciences
6
3%
Immunology and Microbiology
5
3%
Other
24
13%
Unknown
55
30%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 46. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2025.
All research outputs
#1,055,051
of 29,400,575 outputs
Outputs from The Lancet Respiratory Medicine
#673
of 3,177 outputs
Outputs of similar age
#9,105
of 252,639 outputs
Outputs of similar age from The Lancet Respiratory Medicine
#5
of 45 outputs
Altmetric has tracked 29,400,575 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,177 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 75.2. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 252,639 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.
